The methodology and application of Mendelian randomization to study causal mechanisms in health and disease has developed dramatically over the last decade. New methods, large-scale genome-wide analyses, molecular epigenetics, and other new -omics technologies are all providing exceptional opportunities for the exploitation of Mendelian randomization approaches to understand causes of complex traits and disease outcomes. This research has the potential to identify new approaches for the prevention and treatment of common conditions.
Mendelian randomization: where are we now and where are we going?
Stephen Burgess*, Nicholas J Timpson*, Shah Ebrahim, George Davey Smith
The methodology and application of Mendelian randomization to study causal mechanisms in health and disease has developed dramatically over the last decade. New methods, large-scale genome-wide analyses, molecular epigenetics, and other new -omics technologies are all providing exceptional opportunities for the exploitation of Mendelian randomization approaches to understand causes of complex traits and disease outcomes. This research has the potential to identify new approaches for the prevention and treatment of common conditions.
The origins of what is now termed "Mendelian randomization" (Figure 1 , see caption for assumptions) can be traced back over half a century 1 , although the first extended presentation of the principles was in this journal just over a decade ago 2 . Since then it has become a widely utilized methodology, with publications covering many branches of biomarker 3 4 5 6 7 8 9 10 11 12 , behavioural 13 14 15 16 , and infectious disease 17 18 epidemiology. Mendelian randomization studies with clear implications for pharmacotherapeutics are also becoming commonplace 19 20 21 , and applications to social science and to economics (the field in which the statistical technique of instrumental variables analysis central to Mendelian randomization was initially conceived 22 ) are being developed 23 24 .
Methodological advances
Over the past few years, several methodological advances have been made. The basic assumption -that genetic variants which can proxy for a potentially modifiable exposure are essentially unrelated to confounding factors -has been demonstrated to have widespread plausibility 25 . The connection between the standard Mendelian randomization experiment and the theory of instrumental variables has been elaborated upon 26 27 . Extensions to use multiple genetic variants for increasing power and investigating the influence of pleiotropy have been theorized 28 and implemented 29 30 31 32 . Bidirectional Mendelian randomization for informing the direction of causal effects has been exemplified 33 34 and extended to consider more complex networks 35 . Methods for the estimation of non-linear causal effects have been proposed 36 37 . Causal effects of related phenotypes with common genetic predictors in a multivariable analysis framework have been estimated 38 39 . Factorial Mendelian randomization to investigate the combined effect of treatments with separate genetic proxies has been undertaken 40 . Sensitivity analyses for investigating the biasing effects of pleiotropy have been developed 41 42 . Extensions to consider gene-by-environment interactions have been outlined and applied 43 44 45 . The integration of epigenetic profiles as an intermediate phenotype has been proposed 46 47 and implemented 48 49 . The development of Mendelian randomization into the hypothesis-free resolution of causal directions in correlated networks has been outlined 50 . In summary, methodological development has been undertaken in response to the challenges of new substantive applied questions and increasingly detailed genetic data. This development has enabled (and continues to enable) more sophisticated questions to be answered using the framework of Mendelian randomization. 56 57 . This allows the efficient evaluation of causal effects in large sample sizes without requiring sharing of individual-level data.
Mendelian randomization in the post-GWAS era
As it is not required for the phenotype and outcome in two-sample Mendelian randomization to be estimated on the same individuals, genetic associations with the phenotype and outcome can be taken from large consortia, thus potentially greatly increasing power compared with a one-sample
Mendelian randomization analysis 51 .
Over the last decade, the heritability of many complex traits has been explored using GWAS. In general, common genetic variants have small effects on complex traits. In the recently completed UK10K study (www.uk10k.org), novel genetic variants with relatively large phenotypic effects were observed 58 . However, large effect sizes seemed to be confined to the rarest detectable signals and, for the most part, effects attributable to common genetic variants were small. This is rather disappointing from the viewpoint of developing predictive tools for even highly heritable traits. Studies like UK10K assessing the genetic architecture of complex traits more thoroughly through sequencing suggest that, for complex traits, this picture is unlikely to change. But even variants with modest effect sizes provide opportunities for the investigation of potential novel causal pathways using Mendelian randomization, particularly given the development of novel statistical tools for detecting and adjusting for pleiotropy from multiple genetic variants 41 .
The promise of -omics
Mendelian randomization studies have generally focused on a limited number of intermediate phenotypes,
but recent applications of omic technologies into large scale population based studies present new opportunities for identifying novel predictive biomarkers and causal links between established phenotypes and disease outcomes 47 59 60 61 62 63 . Both metabolomics and DNA methylation data are increasingly being exploited 49 64 .
Metabolomic data, representing multiple metabolic pathways in systemic metabolism, can be quantified by targeted mass spectroscopy or by proton nuclear magnetic resonance spectroscopy. With this, it has been possible to examine the causal role of risk factors such as body mass index (BMI) in the formation of metabolomic profiles and thus to consider the finer aetiology of possible disease effects 65 . Furthermore, many metabolites have substantial heritability and robust genetic variant associations have already been identified 66 67 . Metabolite profiles have proved useful in the prediction of cardiometabolic disease 68 69 , although their role as modifiable targets for intervention or causal mediators of disease risk is unclear 49 . The availability of genetic instruments for many metabolites provides opportunities to assess the causal effects of metabolites on disease risk. Both bi-directional (see above) and hypothesis-generating (see below)
applications of Mendelian randomisation are likely to be useful in exploiting these data.
Methylation of DNA is a partially stable mechanism for gene regulation, occurring from the earliest stages of development onwards, under genetic, environmental and stochastic influences 70 . In a similar way to metabolomic data, the availability of large collections of genome-wide epigenetic data marks presents a valuable opportunity to consider the role of gene regulation in the aetiology of complex disease. In this case, methylation related genetic variants (mQTLs) are used as proxy markers of DNA regulatory variation, which may be causally implicated in diseases. A theoretical framework for this work has been developed 46 71 and applied 48 49 . (Figure 2) As well as being potential targets for intervention, both metabolomic 72 73 and methylation data may serve as indicators of exposure to difficult-to-measure intermediate phenotypes. In the case of DNA methylation data in particular, these could provide proxy measures of long term 74 or critical period exposure 75 76 that could otherwise not be assessed on large population samples.
Taxonomy of Mendelian randomization investigations
Limitations in our understanding of genetic variants used in Mendelian randomization has led to suggestions that evidence from Mendelian randomization studies in informal evidence synthesis should be downweighted 77 78 79 . However, not all applications of Mendelian randomization are the same in terms of their aims, procedures and quality of evidence generated. We provide a taxonomy of Mendelian randomization investigations into three broad categories, based largely on the nature of the intermediate phenotype evaluated, and the biological plausibility of the genetic variants for use in assessing causal effects. These categories are presented separately but form a spectrum of evidence quality, as some investigations will not fall neatly into a single category.
Validation of potential drug targets
Some phenotypes have a genetic aetiology dominated by a relatively small number of key coding or functionally relevant loci (such as C-reactive protein 3 , interleukin-6 19 20 , lipoprotein-associated phospholipase A2 80 , or secretory phospholipase A2 81 , bilirubin 82 There are several examples of Mendelian randomization investigations relevant to pharmacological investigations. Drugs to inhibit C-reactive protein were not developed further after Mendelian randomization experiments demonstrated no causal role of C-reactive protein in cardiovascular disease 86 3 .
In contrast, interleukin-6 receptor can be blocked by a monoclonal antibody (tocilizumab) which was developed for the treatment of rheumatoid arthritis. A variant in the IL6R gene region shows an association with coronary heart disease risk 87 88 , so consequently tocilizumab would be worthwhile taking forward into trials for cardiovascular risk prevention 89 . As another example, statins are associated with an increased risk of type 2 diabetes. A Mendelian randomization study using genetic variants coding for HMGCoA reductase (the protein target that is inhibited by statins) demonstrated that these variants were associated with an increase in type 2 diabetes 90 91 . The inference from these findings is that attempts to make statins more specific and thereby reduce off -target effects will not avoid the increased risk of the diabetes. Genetic variants in the CETP gene region have been used as proxies for cholesterylester transfer protein (CETP)
inhibitors, such as dalcetrapib 92 . These drugs are developed to raise high-density lipoprotein cholesterol levels. Variants in the CETP region have shown null associations with coronary artery disease risk 21 , although null associations with blood pressure suggest that the blood pressure-increasing effect of torcetrapib 93 is an off-target effect rather than a downstream consequence of CETP inhibition 94 .
A recent investigation to assess the impact of interleukin-1 inhibition (e.g. by use of the drug anakinra, which is beneficial in rheumatoid arthritis) on cardio-metabolic disorders found that genetic variants which proxy the effects of sustained dual interleukin-1α/β inhibition were associated with an increased risk of cardiovascular diseases 95 . Two notable aspects of this investigation are the use of positive control variables, and the consideration of multiple outcomes. Clinical trials of anakinra show decreases in C-reactive protein and interleukin-6 levels that are also predicted by the associations of the genetic variants. The concordant associations with these positive controls increase the plausibility that the genetic variants are good proxies for the pharmacological intervention. The investigation of large numbers of outcomes, made practical by publically-available GWAS data, enables both the search for potential causal mediators of disease risk (in this case, proatherogenic lipids), and drug repositioning. Here, rather than finding another disease outcome that may be beneficially treated by anakinra, an important safety signal was discovered. 
Investigation of complex intermediate phenotypes

Hypothesis-generating investigations
A final category of analyses (which some may feel are not true Mendelian randomization analyses) are termed "hypothesis-generating investigations". As with GWAS studies, these are undertaken particularly for intermediate phenotypes that do not have strong known genetic determinants, such as educational attainment 99 100 . Automated analyses of associations between a range of risk factors and outcomes have been undertaken using whole genome scores 101 and using summarized data from across the whole genome 102 , to investigate whether common genetic predictors correlate with phenotypic and outcome traits. Such investigations have given mixed results, and should be regarded as hypothesis-generating rather than assessments of causation. Nonetheless, they represent a natural extension to the methods of Mendelian randomization to obtain more speculative, but potentially findings with greater statistical power if the genetic predictors explain more variation in the phenotype. To this end, the application of automated two-sample
Mendelian randomization in a hypothesis-generating approach is likely to expand rapidly the capacity of conventional epidemiology to generate plausible hypotheses. In this case, derived genetic instruments may be exported to existing, large, GWAS collections of any disease or outcome and employed to give estimates of the causal implications of exposure to novel modifiable risk factors. This would yield a potential return on the large collections of genetic variant data in the GWAS community which are, as yet, underutilised.
In this themed issue of the journal we have published both methodological developments and substantive findings from many research groups. Methodology for improving quality of reporting 103 , bias detection due to invalid instruments 41 , and mediation in causal pathways 35 are covered. The effects of a wide range of intermediate phenotypes on disease outcomes using genetic instruments are also examined. These range from tobacco (smoking does lower body weight) 104 , coffee 105 , milk 106 and alcohol 107 intakes, obesity 108 109 , vitamin D 110 and testosterone 111 112 . These analyses using genetic instruments provide an alternative means of examining causal associations, particularly in circumstances where associations are likely to be heavily confounded and randomized experiments are not feasible.
Caution and conclusion
Potential limitations of the Mendelian randomization strategy were discussed extensively in its initial formal presentation 2 and have been reiterated elsewhere 113 114 115 116 . Largely as a function of the potentially overwhelming collection of genetic variants presented to the epidemiologist looking to practice Mendelian randomization, the potential to fall into one of a series of analytical traps has been increased. Power, linkage disequilibrium, pleiotropy, canalization and population stratification have all been recognised as potential flaws in the Mendelian randomization approach as methods have been developed. Whilst avoidance strategies for these limitations are now really beginning to appear, further limitations are being realised. In circumstances where we are less likely to have well-characterised, candidate driven, and biologically understood genetic variants as instruments, it is tempting to use the totality of available variants in an analysis, for example in a genetic risk score approach 117 . Whilst it is attractive at the outset to amalgamate genetic variants into comprehensive genetic scores which have the potential to increase variance in the phenotype explained (and thus increase power) 118 , it is increasingly clear is that where these scores are not understood completely, the potential for inferential complication is greater now than ever.
Using the example of educational attainment, large-scale GWAS meta-analysis has successfully identified genetic variants reliably correlated with education 99 . However, these signals represent a small fraction of the total variability in educational attainment 100 . Genome-wide predictors will enhance the power of a
Mendelian randomization analysis, with genetic scores including all variants (even those not associated at a conventional level of significance) explaining around 3% of the variance. (See Figure 3) . However, as a result of the combined impact of linkage disequilibrium, genetic contributions from many different biological pathways, and the possible biasing effects of pleiotropy, the use of such a genome-wide estimator may sadly produce effect estimates which suffer the similar limitations as a more conventional, observational, estimate.
The next decade will see a deeper understanding of the properties of genetic variants which will be is crucial to the appropriate implementation and interpretation of Mendelian randomization analyses. Over the last decade, Mendelian randomization has provided a novel and flexible paradigm to understand the causal nature of associations between modifiable risk factors and common diseases. Mendelian randomization has made use of the massive investment in human genetic research, focusing on causal mechanisms that have the promise of identifying worthwhile targets for pharmacological research and for preventive public health interventions that are already making a difference and will continue to do so in the coming decade. Mendelian randomization: using genetic variants as instrumental variables to establish whether an exposure is causally related to a disease or trait.
(A) The genotype acts as an instrumental variable if: i) it is associated with the exposure, ii) it is independent of measured or unmeasured confounders, and iii) it can only influence that outcome via the causal effect of the exposure.
(B) Under the instrumental variable assumptions, the lack of association between the C-reactive protein genotype and disease risk indicates that C-reactive protein is not a causal risk factor for ischaemic heart disease. An association between the genotype and disease outcome would indicate a causal relationship of the exposure on the outcome. B -Two-sample/two-step Mendelian randomization: We consider tissue specific DNA methylation as a potentially causal intermediate phenotype. In a potentially smaller first sample the association of the exposure to DNA methylation is established using a Mendelian randomization approach (with the exposure-related SNP 1). A genetic variant associated with the same methylation difference but not related to the exposure is identified (SNP 2). In a potentially larger second sample the exposure is shown to influence the outcome through the use of SNP 1, and the exposure-related methylation is shown to influence the outcome through the use of SNP 2. 
